Seattle-based biotechnology company Dendreon (NASDAQ:DNDN), maker of the prostate cancer treatment Provenge, was hacked by almost 40% Thursday after reporting a third-quarter revenue loss of $147.1 million, or $1 per share, almost doubly worse than a year ago.
Guidance further soured investors, with the company reporting that while sales were up 5.6% in October from a month ago, November’s sales would be less than October’s. The company, hoping to stem the tide from its big-ticket drug Provenge to Johnson & Johnson’s (NYSE:JNJ) less expensive prostate medicine Zytiga, is turning to patients by expanding consumer advertising.
DNDN stock, which started Thursday trading above $10, bottomed out at $6.47 before finishing the day at $6.55.
Meanwhile, fashion retailer Abercrombie & Fitch (NYSE:ANF) dished out some bad news of its own, reporting same-store sales at its flagship stores in Europe, Canada and Japan were on the decline for the third quarter, causing Janney Montgomery Scott to downgrade Abercrombie to “neutral” from “buy” and sending ANF stock spiraling down about 20%.
Abercrombie’s revenue at all stores open at least a year actually was up 7%, higher than FactSet analysts’ estimate of 6.3%, but the poor international showing dampened the news. ANF stock finished Thursday at $59.26, down from just more than $70, while rival American Eagle (NYSE:AEO) finished the day up almost 7% at $14.03.
- Estee Lauder (NYSE:EL): Up 18% ($18.15) to $118.98.
- Alpha Natural Resources (NYSE:ANR): Up 13.29% ($3.18) to $27.11.
- Green Mountain Coffee Roasters (NASDAQ:GMCR): Up 8.48% ($5.23) to $66.90.
- Transocean (NYSE:RIG): Down 12.48% ($6.69) to $49.00.
- Kellogg Co. (NYSE:K): Down 7.64% ($4.13) to $49.91.
- MGM Resorts International (NYSE:MGM): Down 5.79% (66 cents) to $10.73.
As of this writing, Kyle Woodley did not own a position in any of the aforementioned stocks. Check out recaps from previous trading days here.